AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 10377733 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon (IFN) therapy for chronic hepatitis C: protocols changed over time from 3 x 3 MU for 6 months to 3 x 3 MU for 12 months, including combination with ribavirin
Number of subjects: 1122
Study 9193433 — intervention group
Group type: EXPERIMENTAL
Intervention: Early ramipril (10 mg)
Number of subjects: 352
Study 9193433 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose ramipril (0.625 mg)
Number of subjects: 352
Study 9193433 — intervention group
Group type: EXPERIMENTAL
Intervention: Delayed ramipril (10 mg, day 14)
Number of subjects: 352
Study 9193433 — intervention group
Group type: COMPARATOR
Intervention: Both ramipril groups
Number of subjects: 352
Study 7681899 — intervention group
Group type: EXPERIMENTAL
Intervention: Diltiazem controlled release (b.i.d.)
Number of subjects: 49
Study 7681899 — intervention group
Group type: COMPARATOR
Intervention: Standard diltiazem (t.i.d. or q.i.d.)
Number of subjects: 49
Study 7681899 — intervention group
Group type: EXPERIMENTAL
Intervention: Both formulations
Number of subjects: 49
Study 3959968 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 mg buprenorphine
Number of subjects: 0
Study 3959968 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 mg buprenorphine
Number of subjects: 0
Study 3959968 — intervention group
Group type: EXPERIMENTAL
Intervention: Abrupt cessation of buprenorphine
Number of subjects: 0
Study 3959968 — intervention group
Group type: EXPERIMENTAL
Intervention: Reintroduction of buprenorphine
Number of subjects: 0
Study 3959968 — intervention group
Group type: EXPERIMENTAL
Intervention: Urine assay for opiate drugs
Number of subjects: 0
Study 31164431 — intervention group
Group type: EXPERIMENTAL
Intervention: Pirfenidone
Number of subjects: 0
Study 31164431 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 29248266 — intervention group
Group type: EXPERIMENTAL
Intervention: PCV7
Number of subjects: 0
Study 29248266 — intervention group
Group type: EXPERIMENTAL
Intervention: PCV13
Number of subjects: 0
Study 29248266 — intervention group
Group type: EXPERIMENTAL
Intervention: PCV7 and PCV13
Number of subjects: 0
Study 26490132 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-SCPC HCAZ
Number of subjects: 230
Study 26490132 — intervention group
Group type: EXPERIMENTAL
Intervention: HCAZ increase from enrollment to pre-SCPC
Number of subjects: 230
Study 26490132 — intervention group
Group type: COMPARATOR
Intervention: Asymmetric growth indices
Number of subjects: 230
Study 24947255 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevacizumab plus lomustine and SOC (third line and beyond)
Number of subjects: 0
Study 24947255 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus lomustine and then placebo plus SOC
Number of subjects: 0
Study 22516850 — intervention group
Group type: EXPERIMENTAL
Intervention: Yi Ren Medical Qigong (YRMQ)
Number of subjects: 32
Study 19818957 — intervention group
Group type: EXPERIMENTAL
Intervention: Unipedicular Kyphoplasty (KP)
Number of subjects: 58
Study 19818957 — intervention group
Group type: EXPERIMENTAL
Intervention: Bipedicular Kyphoplasty (KP)
Number of subjects: 58
Study 18499299 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer-based dermatology tutorial (Group 1)
Number of subjects: 73
Study 18499299 — intervention group
Group type: COMPARATOR
Intervention: Traditional lecture on skin morphology (Group 2)
Number of subjects: 73
Study 15977464 — intervention group
Group type: EXPERIMENTAL
Intervention: Risedronate 5 mg daily
Number of subjects: 3331
Study 12707876 — intervention group
Group type: EXPERIMENTAL
Intervention: Pelvic floor exercises (PFXs)
Number of subjects: 720
Study 11279974 — intervention group
Group type: EXPERIMENTAL
Intervention: Histamine (0.1 to 1 ng, subcutaneous administration, twice a week for 12 weeks)
Number of subjects: 60
Study 11279974 — intervention group
Group type: COMPARATOR
Intervention: Placebo (subcutaneous administration, twice a week for 12 weeks)
Number of subjects: 60
Study 9546933 — intervention group
Group type: EXPERIMENTAL
Intervention: Regression equations for predicting claudication pain distances based on ABI, body mass index, gender, and smoking status.
Number of subjects: 272
Study 9546933 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-reported distances to onset and maximal claudication pain.
Number of subjects: 272
Study 1578306 — intervention group
Group type: EXPERIMENTAL
Intervention: Alternate-day corticosteroid therapy
Number of subjects: 35
Study 1578306 — intervention group
Group type: COMPARATOR
Intervention: Daily corticosteroid regimen
Number of subjects: 35
Study 1578306 — intervention group
Group type: COMPARATOR
Intervention: Daily corticosteroid regimen (after switching to alternate-day therapy)
Number of subjects: 35
Study 1578306 — intervention group
Group type: EXPERIMENTAL
Intervention: Alternate-day corticosteroid therapy (continued from the outset)
Number of subjects: 35
Study 2859648 — intervention group
Group type: EXPERIMENTAL
Intervention: Blockade of histamine receptors with Fenistil plus Tagamet
Number of subjects: 2250
Study 31213443 — intervention group
Group type: EXPERIMENTAL
Intervention: FES cycling and goal-directed functional exercises with a physiotherapist, plus recreational cycling at home, for 8 weeks (2 sessions per week).
Number of subjects: 40
Study 31213443 — intervention group
Group type: COMPARATOR
Intervention: Usual care (waitlist control group).
Number of subjects: 40
Study 28778829 — intervention group
Group type: EXPERIMENTAL
Intervention: Portable powered ankle-foot orthosis (PPAFO)
Number of subjects: 16
Study 28778829 — intervention group
Group type: COMPARATOR
Intervention: Passive ankle-foot orthosis (AFO)
Number of subjects: 16
Study 28778829 — intervention group
Group type: COMPARATOR
Intervention: Shoes (no AFO)
Number of subjects: 16
Study 27020487 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic intravenous ephedrine 10mg (Group E)
Number of subjects: 168
Study 27020487 — intervention group
Group type: EXPERIMENTAL
Intervention: Ondansetron 8mg (Group O)
Number of subjects: 168
Study 27020487 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (Group P)
Number of subjects: 168
Study 27020487 — intervention group
Group type: EXPERIMENTAL
Intervention: Group E and Group O
Number of subjects: 168
Study 23702697 — intervention group
Group type: EXPERIMENTAL
Intervention: IVIG (1-2 g/kg, over 2 days)
Number of subjects: 15
Study 23702697 — intervention group
Group type: EXPERIMENTAL
Intervention: IVIG
Number of subjects: 15
Study 23702697 — intervention group
Group type: COMPARATOR
Intervention: Untreated
Number of subjects: 15
Study 22884767 — intervention group
Group type: EXPERIMENTAL
Intervention: Exenatide QW (2 mg)
Number of subjects: 427
Study 22884767 — intervention group
Group type: COMPARATOR
Intervention: Insulin glargine (starting dose, 4 U)
Number of subjects: 427
Study 21344812 — intervention group
Group type: EXPERIMENTAL
Intervention: Calf stretching box
Number of subjects: 80
Study 21344812 — intervention group
Group type: COMPARATOR
Intervention: Conventional exercise method
Number of subjects: 80
Study 18041508 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational interviewing (MI)
Number of subjects: 240
Study 18041508 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 240
Study 16044784 — intervention group
Group type: EXPERIMENTAL
Intervention: Evidence-based medicine (EBM) methods of comparison
Number of subjects: 0
Study 16044784 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognition-based medicine (CBM)
Number of subjects: 0
Study 16044784 — intervention group
Group type: COMPARATOR
Intervention: Randomised controlled trials
Number of subjects: 0
Study 16044784 — intervention group
Group type: COMPARATOR
Intervention: Meta-analyses
Number of subjects: 0
Study 16044784 — intervention group
Group type: EXPERIMENTAL
Intervention: Complementary approach of different evaluation methods
Number of subjects: 0
Study 12898879 — intervention group
Group type: EXPERIMENTAL
Intervention: Traditional nursing model
Number of subjects: 0
Study 12898879 — intervention group
Group type: COMPARATOR
Intervention: Modern nursing model (nursing process)
Number of subjects: 0
Study 10524884 — intervention group
Group type: COMPARATOR
Intervention: 4 mg doxazosin
Number of subjects: 82
Study 10524884 — intervention group
Group type: EXPERIMENTAL
Intervention: 8 mg doxazosin
Number of subjects: 82
Study 7696941 — intervention group
Group type: EXPERIMENTAL
Intervention: 60 mg aspirin daily
Number of subjects: 9364
Study 7696941 — intervention group
Group type: COMPARATOR
Intervention: Matching placebo
Number of subjects: 9364
Study 2045466 — intervention group
Group type: EXPERIMENTAL
Intervention: High fat modern diet (carbohydrate 30%, fat 50%, protein 20%)
Number of subjects: 24
Study 2045466 — intervention group
Group type: COMPARATOR
Intervention: Traditional Pima diet (carbohydrate 70%, fat 15%, protein 15%)
Number of subjects: 24
Study 7043753 — intervention group
Group type: EXPERIMENTAL
Intervention: CMFVP (cyclophosphamide + methotrexate + fluoro‐uracil + vincristine + prednisone)
Number of subjects: 81
Study 7043753 — intervention group
Group type: COMPARATOR
Intervention: CMF (cyclophosphamide + methotrexate + fluoro‐uracil)
Number of subjects: 81
Study 7043753 — intervention group
Group type: COMPARATOR
Intervention: CMF + MER (immunotherapy with methanol extract residue of BCG)
Number of subjects: 81
Study 30993573 — intervention group
Group type: EXPERIMENTAL
Intervention: Bariatric surgery in patients aged ≥ 60 years (case group)
Number of subjects: 216
Study 30993573 — intervention group
Group type: COMPARATOR
Intervention: Bariatric surgery in patients aged ≤ 50 years (control group)
Number of subjects: 216
Study 29784470 — intervention group
Group type: EXPERIMENTAL
Intervention: MenACWY-TT (3+1 schedule at ages 2, 4, 6 and 15-18 months)
Number of subjects: 750
Study 29784470 — intervention group
Group type: EXPERIMENTAL
Intervention: MenACWY-TT (1+1 schedule at 6 and 15-18 months)
Number of subjects: 750
Study 29784470 — intervention group
Group type: EXPERIMENTAL
Intervention: MenACWY-TT (single-dose at 15-18 months)
Number of subjects: 750
Study 29784470 — intervention group
Group type: EXPERIMENTAL
Intervention: MenACWY-TT (all groups)
Number of subjects: 750
Study 29784470 — intervention group
Group type: COMPARATOR
Intervention: Routine childhood vaccines (PHiD-CV and DTPa-IPV/Hib)
Number of subjects: 750
Study 29784470 — intervention group
Group type: COMPARATOR
Intervention: All groups (MenACWY-TT and routine vaccines)
Number of subjects: 750
Study 27569651 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg hydrocortisone
Number of subjects: 60
Study 27569651 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 24686957 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-affirmation intervention
Number of subjects: 80
Study 24686957 — intervention group
Group type: COMPARATOR
Intervention: Non-affirmation condition
Number of subjects: 80
Study 22903909 — intervention group
Group type: EXPERIMENTAL
Intervention: Group music therapy for 10 weeks
Number of subjects: 17
Study 22903909 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention during the study)
Number of subjects: 17
Study 20524885 — intervention group
Group type: EXPERIMENTAL
Intervention: Mood-management intervention
Number of subjects: 1000
Study 20524885 — intervention group
Group type: COMPARATOR
Intervention: Control group (no mood-management tool)
Number of subjects: 1000
Study 17884598 — intervention group
Group type: EXPERIMENTAL
Intervention: Implicit self-comparisons against self at an earlier time, against healthy peers, or against ill patients
Number of subjects: 0
Study 15686573 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlated linguistic cues
Number of subjects: 0
Study 15686573 — intervention group
Group type: COMPARATOR
Intervention: No correlated linguistic cues
Number of subjects: 0
Study 12088814 — intervention group
Group type: EXPERIMENTAL
Intervention: 7% sevoflurane with 50% N(2)O
Number of subjects: 40
Study 12088814 — intervention group
Group type: COMPARATOR
Intervention: Intravenous midazolam 0.1 mg/kg followed by 7% sevoflurane with 50% N(2)O
Number of subjects: 40
Study 9569075 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular methylprednisolone acetate (i.m. MP) 120 mg 3-weekly
Number of subjects: 60
Study 9569075 — intervention group
Group type: COMPARATOR
Intervention: Oral prednisolone (OP) initial dose 15 mg, gradually tapering
Number of subjects: 60
Study 9569075 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular methylprednisolone acetate (i.m. MP)
Number of subjects: 60
Study 9569075 — intervention group
Group type: COMPARATOR
Intervention: Oral prednisolone (OP)
Number of subjects: 60
Study 8547555 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg of intrapleural morphine (IPM group)
Number of subjects: 28
Study 8547555 — intervention group
Group type: COMPARATOR
Intervention: 20 mg of intravenous morphine (IVM group)
Number of subjects: 28
Study 2797892 — intervention group
Group type: EXPERIMENTAL
Intervention: Ivermectin
Number of subjects: 30
Study 2797892 — intervention group
Group type: EXPERIMENTAL
Intervention: Diethylcarbamazine (DEC)
Number of subjects: 30
Study 2797892 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 523421 — intervention group
Group type: EXPERIMENTAL
Intervention: Ethambutol (25 mg/kg daily) for 8 days in healthy subjects
Number of subjects: 46
Study 523421 — intervention group
Group type: EXPERIMENTAL
Intervention: Ethambutol plus isoniazid plus rifampicin for 6 months
Number of subjects: 46
Study 523421 — intervention group
Group type: COMPARATOR
Intervention: Streptomycin plus isoniazid plus PAS for 3 months, then streptomycin plus isoniazid plus ethambutol for another 3 months
Number of subjects: 46
Study 31896529 — intervention group
Group type: EXPERIMENTAL
Intervention: Antidepressant medications (ADM)
Number of subjects: 433
Study 31896529 — intervention group
Group type: EXPERIMENTAL
Intervention: Both Antidepressant medications (ADM) and Cognitive therapy (CT)
Number of subjects: 433
Study 31896529 — intervention group
Group type: COMPARATOR
Intervention: Cognitive therapy (CT)
Number of subjects: 433
Study 30611343 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous infusion of 15 mg/kg of tranexamic acid (TXA)
Number of subjects: 80
Study 30611343 — intervention group
Group type: COMPARATOR
Intervention: Control group (no TXA)
Number of subjects: 80
Study 28278717 — intervention group
Group type: EXPERIMENTAL
Intervention: Directly observed therapy (DOT) with intermittent, high-dose Vitamin D3
Number of subjects: 0
Study 28278717 — intervention group
Group type: COMPARATOR
Intervention: Standard of care (SOC)
Number of subjects: 0
Study 25443996 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise in addition to usual care (n=39): 12-week exercise programme involving three, 30-min resistance-training sessions/week and a pedometer-based walking programme.
Number of subjects: 81
Study 25443996 — intervention group
Group type: COMPARATOR
Intervention: Usual care (n=42): psychotherapy, pharmaceutical interventions, and group therapy.
Number of subjects: 81
Study 25443996 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise in addition to usual care (n=39)
Number of subjects: 81
Study 25443996 — intervention group
Group type: COMPARATOR
Intervention: Usual care (n=42)
Number of subjects: 81
Study 23879277 — intervention group
Group type: EXPERIMENTAL
Intervention: 150 ms AVD
Number of subjects: 31
Study 23879277 — intervention group
Group type: COMPARATOR
Intervention: Minimizing right ventricular pacing (MRVP)
Number of subjects: 31
Study 21283981 — intervention group
Group type: EXPERIMENTAL
Intervention: Endovenous laser ablation (EVLA)
Number of subjects: 280
Study 21283981 — intervention group
Group type: COMPARATOR
Intervention: Conventional surgery
Number of subjects: 280
Study 19760753 — intervention group
Group type: EXPERIMENTAL
Intervention: Phlebotomies to obtain a ferritin level <50 ng/mL followed by pegylated‐Interferon alpha2b + ribavirin
Number of subjects: 33
Study 19760753 — intervention group
Group type: COMPARATOR
Intervention: Pegylated‐Interferon alpha2b + ribavirin
Number of subjects: 33
Study 19760753 — intervention group
Group type: EXPERIMENTAL
Intervention: Phlebotomies
Number of subjects: 33
Study 19760753 — intervention group
Group type: EXPERIMENTAL
Intervention: Phlebotomies and antiviral therapy
Number of subjects: 33
Study 16720167 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic surgery
Number of subjects: 90
Study 16720167 — intervention group
Group type: EXPERIMENTAL
Intervention: Stereotactic aspiration
Number of subjects: 90
Study 16720167 — intervention group
Group type: COMPARATOR
Intervention: Craniotomy
Number of subjects: 90
Study 15592115 — intervention group
Group type: EXPERIMENTAL
Intervention: Acuvue 2
Number of subjects: 62
Study 15592115 — intervention group
Group type: EXPERIMENTAL
Intervention: Acuvue Advance
Number of subjects: 62
Study 15592115 — intervention group
Group type: EXPERIMENTAL
Intervention: Focus Night & Day
Number of subjects: 62
Study 15592115 — intervention group
Group type: COMPARATOR
Intervention: Control (no lenses)
Number of subjects: 62
Study 11693012 — intervention group
Group type: EXPERIMENTAL
Intervention: Preventive dental program (PDP)
Number of subjects: 136
Study 11693012 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 136
Study 9389947 — intervention group
Group type: EXPERIMENTAL
Intervention: Clindamycin hydrochloride capsules, 150 mg by mouth four times daily for 7 consecutive days.
Number of subjects: 139
Study 9389947 — intervention group
Group type: COMPARATOR
Intervention: Placebo (partner treatment).
Number of subjects: 139
Study 9389947 — intervention group
Group type: EXPERIMENTAL
Intervention: Clindamycin hydrochloride capsules, 150 mg by mouth four times daily for 7 consecutive days (among women cured by the first week's visit).
Number of subjects: 139
Study 9389947 — intervention group
Group type: COMPARATOR
Intervention: Placebo (partner treatment, among women cured by the first week's visit).
Number of subjects: 139
Study 7707159 — intervention group
Group type: EXPERIMENTAL
Intervention: Twice a day slow-release nifedipine
Number of subjects: 113
Study 7707159 — intervention group
Group type: COMPARATOR
Intervention: Once a day amlodipine
Number of subjects: 113
Study 7707159 — intervention group
Group type: EXPERIMENTAL
Intervention: Both regimens
Number of subjects: 113
Study 2451968 — intervention group
Group type: EXPERIMENTAL
Intervention: Dextran 70 and Dihydroergotamine (DHE)
Number of subjects: 45
Study 2451968 — intervention group
Group type: COMPARATOR
Intervention: Dextran 70 alone
Number of subjects: 45
Study 2451968 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 45
Study 29100903 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibiotics (n=34)
Number of subjects: 122
Study 29100903 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n=34)
Number of subjects: 122
Study 29100903 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibiotics (n=32)
Number of subjects: 122
Study 29100903 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n=30)
Number of subjects: 122
Study 27353441 — intervention group
Group type: EXPERIMENTAL
Intervention: Demineralized freeze-dried bone allograft (DFDBA)
Number of subjects: 36
Study 27353441 — intervention group
Group type: COMPARATOR
Intervention: Platelet-rich fibrin (PRF)
Number of subjects: 36
Study 25802953 — intervention group
Group type: EXPERIMENTAL
Intervention: Strengthening exercise group (n = 15)
Number of subjects: 30
Study 25802953 — intervention group
Group type: EXPERIMENTAL
Intervention: Proprioceptive-balance exercise group (n = 15)
Number of subjects: 30
Study 25802953 — intervention group
Group type: COMPARATOR
Intervention: Intergroup analysis between strengthening and proprioceptive-balance exercise groups
Number of subjects: 30
Study 23876062 — intervention group
Group type: EXPERIMENTAL
Intervention: Capecitabine (1000 mg/m2 orally BID, days 1 to 14 of 21) in combination with Sorafenib (600 mg/day orally BID, days 1 to 21)
Number of subjects: 519
Study 23876062 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 519
Study 23876062 — intervention group
Group type: EXPERIMENTAL
Intervention: Capecitabine and Sorafenib
Number of subjects: 519
Study 21070639 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined physical exercise and psychosocial intervention program
Number of subjects: 100
Study 21070639 — intervention group
Group type: COMPARATOR
Intervention: Care as usual (control)
Number of subjects: 100
Study 18180683 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclosporine 0.05% ophthalmic emulsion (Restasis; Allergan, Inc.) used twice daily
Number of subjects: 0
Study 18180683 — intervention group
Group type: COMPARATOR
Intervention: Placebo group receiving rewetting drops (Refresh Preservative Free Artificial Tears; Allergan, Inc.) used twice daily
Number of subjects: 0
Study 16595148 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin/cyclophosphamide
Number of subjects: 101
Study 15192065 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaginal misoprostol 800 microg
Number of subjects: 154
Study 15192065 — intervention group
Group type: COMPARATOR
Intervention: Curettage
Number of subjects: 154
Study 11729030 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 g/day ethyl eicosapentaenoic acid (EPA)
Number of subjects: 87
Study 11729030 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 87
Study 9209567 — intervention group
Group type: EXPERIMENTAL
Intervention: Active treatment
Number of subjects: 31
Study 8269914 — intervention group
Group type: EXPERIMENTAL
Intervention: Thiamine (50 mg/day)
Number of subjects: 72
Study 8269914 — intervention group
Group type: EXPERIMENTAL
Intervention: Folate (5 mg/day)
Number of subjects: 72
Study 8269914 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 72
Study 8269914 — intervention group
Group type: EXPERIMENTAL
Intervention: Both vitamins (Thiamine and Folate)
Number of subjects: 72
Study 8269914 — intervention group
Group type: COMPARATOR
Intervention: Placebo (two tablets per day)
Number of subjects: 72
Study 2957348 — intervention group
Group type: EXPERIMENTAL
Intervention: Teicoplanin 400 mg intravenous bolus
Number of subjects: 120
Study 2957348 — intervention group
Group type: COMPARATOR
Intervention: Control (no intervention specified)
Number of subjects: 120
Study 2957348 — intervention group
Group type: EXPERIMENTAL
Intervention: Amoxycillin 1.0 g intramuscularly
Number of subjects: 120
Study 30033356 — intervention group
Group type: EXPERIMENTAL
Intervention: Lorcaserin 10mg, twice a day for 24 weeks
Number of subjects: 171
Study 30033356 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 171
Study 27448283 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-articular platelet-rich plasma (PRP)
Number of subjects: 315
Study 25418542 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifestyle intervention program using the Japanese-style healthy plate (n=10)
Number of subjects: 19